October 22-23, 2007
NIH Bethesda, Maryland. 3rd reunion from cancer advisory panel for the National Center for Complementary and Alternative Medicine.
Presenters: Ayre S.G., Donato Pérez García Bellón, Donato Pérez García, Hauser R. (Invited by Jeff Whit, MD.)
“Patient summaries for the insulin potentiation therapy best case series”

September 18, 2000
NIH, Bethesda, Maryland. Organized by: The National Institutes of Health’s office of Alternative Medicine (OAM) and The National Cancer Institute (NCI).
Presenters: Ayre S.G., Donato Pérez García Bellón, Donato Pérez García.
“Insulin Potentiation Therapy –Best case series approach”
“Practice Outcomes Monitoring and Evaluation System (POMES) for integrated complementary and alternative medicine cancer practices”.

Washington D.C., Presentation at the third annual comprehensive cancer management conference. By S.G.A. “Primary breast conserving treatment for breast cancer using biologic response modification with insulin in combination with non-toxic low-dose chemotherapy”.

February, 6-9, 1991, Paris, France. The 3rd International Congress on Neo Adjuvant Chemotherapy. Participants: S.G.A, M.D, Donato Pérez García Bellón, M.D, Donato Pérez García Jr. , M.D.
“Insulin Plus Low-Dose CMF as Neo-Adjuvant Chemo Hormonal Therapy for Breast Carcinoma”.

October 24-27, 1989, University of Texas, Houston. Poster abstract at 42 nd Annual Symposium on Fundamental Cancer Center. By: S.G.A, Donato Pérez García y Bellón, Donato Pérez García Jr.

“Breast Carcinoma Treated by a Regimen of Low-Dose Chemotherapy and Insulin: Report of 4 cases and Pharmacokinetic Considerations”.


August 4-6, 1997, Bethesda , Maryland, Medical Hypotheses (20(2):199-210,1986) By: SGA, Donato Pérez García Bellón and Donato Pérez García , Jr.“Insulin Potentiation Therapy: a new concept for management of chronic degenerative disease”.

Radiother Oncol 2006;81(1):112-7

Jordan BF, Beghein N.Crokart N. et al.
“Preclinical safety and efficacy of insulin combined with irradiation”.

Cancer Chemotherapy and Pharmacology
” Insulin induced enhancement of antitumoral response to methotrexate in breast cancer patients”. Lasavio-Prosco E., Cucchi S., Vazquez J., Lasavio- Galante E., Golomar W., Gordon W.

The very first publication of IPT clinical trial data: “IPT very significantly improved clinical outcome of low dose of chemotherapy in patients with advance breast cancer”. December 4, 2003.

“The effect of insulin chemotherapeutic drug sensitivity in human esophageal and lung cancer cells”. Jiao SC, Huang J, Sun Y, Lu SX. Zhonghua Yi Xue Za Zhi.

February 2003.
10;83 (3):195-7 (article in Chinese)
“Insulin significantly enhanced the killing effect of three chemotherapy drugs on esophageal and lung cancer cell’s”.

Medical Hypotheses (2000) 55(4) 330-334, 2000
By: S.G.A, D.P. Garcia Bellon , D.P.Garcia Jr.
“Insulin chemotherapy and the mechanisms of malignancy: the design and the demise of cancer”.

October 1999, pages 94-96
M.D.M Townsend Letter for Doctors and Patients, S.G.A.
“Hoist by one’s own petard: the design and the demise of cancer”.

1981, European Journal of Cancer and Clinical Oncology 17(11):1223-1228.
Alabaster O., Vonderhaar B.K.,Ans Shafie S.M.,
“Metabolic modification by insulin enhances Methotrexate Cytotoxicity in MCF-7 human breast cancer cells”.

 Cancer Chemotherapy Pharmacol.
“Breast Cancer Insulin-Induced Enhancement of Antitumoral Response to Methitrexate in breast cancer patients”. Lasavia-Prisco E., Cucchi S., Vazquez J., Lasalvia-Galante E., Gordon W

1991, Oncology News, 17(4):1, 7.)
“Insulin shows promise as BRM in breast cancer regimens”.

1990, European journal of cancer 26(11-12):1262-3.)
By: S.G.A, Donato Perez Garcia Bellon, Donato Perez Garcia Jr.,
“Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas”.

1989, Medical Hypotheses 29:283-291. By: S.G.Ayre,
“New approaches to the delivery of drugs to the brain”.

January, Res Commun Chem Pathol Pharmacol, 63(1):45-52.
By: S.G.Ayre, Brian Skaletski and Aron D.Mosnaim.
“Blood-brain barrier passage of azidothymidine in rats: effects of insulin”.

May- June 1938. Mexico. Revista Médica Militar, Vol. 1, no.2, , pages 1-77. By Dr. Donato Pérez García (I). “La permeabilidad celular como base en el tratamiento radical de la sífilis: tratamiento de la neuro-sífilis y de la sífilis por insulina”.

(Cellular permeability as a basis for radical treatment of syphilis: treatment for neurosyphilis and syphilis with insulin).

Year unknown, unpublished paper, 84 pages. By Donato Pérez García Bellón. “Mecanismos biológicos, bioquímicos y fisicoquímicos de la insulina que intervienen en la terapéutica donatiana para la curación de los enfermos de cáncer”.

(Biological, biochemical, and physicochemical mechanisms of insulin that take the part on donatian therapy for treating cancer).

1976. By: Drs. Donato Perez Garcia, S.G.A., M.D.,(self-published report, 41 pages). “Cellular Therapy to Change the Biophysical-Biochemical Constants of the Blood, or Donatian Therapy”.

April 10, 1944. Time Magazine, pages 43-44
“Insulin for everything” – article about Donato Perez G. (I)


Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience. C.Damyanov, M.Radoslavova, V.Gavrilov, D.Stoeva. Journal of BUON 14:711-715,2009.
The insulin potentiated therapy (IPT) in the treatment of chronicle and oncological disease. C.Damyanov, M.Radoslavova, V.Gavrilov. Journal MED info. Nov 2008, N:11, p 55-59.
Insulin Potentiation Therapy in the treatment of malignant diseases: a three year study. Chr. Damyanova, MD, PhD, D. Gerasimova, MD, L. Avramov, PhD, Ass.Prof, D. Dyukmedzhieva, MD.  J Cancer Sci Ther 4: 088-091. doi: 10.4172/1948-5956.1000117

Results since 1930 confirm the evidence and there are published scientific studies available showing that this treatment is safe and effective in treating cancer in humans. Insulin Potentiation Targeted Therapy does not have serious side effects.

The use of insulin is safe as reported in a recent article in the New England Journal of Medicine, one of the most respected medical journal in the world. N Engl J Med. 2007 May 3; 256(18):1842-52. Long-term effect of diabetes and its treatment on cognitive function.

*Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group; Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P,Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J.

Conclusions: no evidence of substantial long-term declines in cognitive function was found in a large group of patients with type 1 diabetes who were carefully followed for an average of 18 years, despite relatively high rates of recurrent severe hypoglycemia. ( number, NCT00360893.)copyright 2007 Massachusetts medical society.
PMID: 17476010.